

Press Release



1 March 2017

Insilico and GSK establish a collaboration to promote biomanufacturing of the future

(Stuttgart) – Insilico Biotechnology AG and GSK announce a strategic collaboration that will combine Insilico's leading technology for bioprocess simulation with GSK Vaccine's outstanding expertise and innovation in bioprocess development.

Insilico Biotechnology and GSK have agreed to combine their expertise in early-stage research into industrial processes associated with the development and manufacture of candidate vaccines, in order to further develop a rational, knowledge based approach to this process. Both companies share a commitment to innovative science, breakthrough technology and working in partnership.

Using Insilico's technology platform, predictive simulations of cell responses are analyzed. As a result an almost unlimited number of scenarios will be generated and utilized to significantly reduce the number of experiments necessary during bioprocess development. This has the potential to significantly reduce the time taken to research Vaccine manufacturing processes and could therefore speed up the time-to-market for candidate Vaccines in GSK's research portfolio.

Philippe Dehottay, Head of Microbial Drug Substance, Global Vaccines Technical R&D, GSK said: "Reducing the time taken to bring new Vaccines into development is hugely beneficial, and through this partnership with Insilico we're able to take a rational, knowledge-based approach to developing biological processes which support our innovative research and development pipeline."

"In addition to the expected cost savings, reduced risk, and compressed time lines, the amount of know-how and process understanding that our technology creates will be of enormous value", says Klaus Mauch, Insilico's CEO. "Moreover, the model-based performance analysis of bioprocesses will lead to fast corrective action where necessary and as a result increase the robustness and consistency of production processes."

The collaboration announced today will run for two years and be based at Insilico's sites in Stuttgart, Germany and at GSK's Rixensart, Belgium location.

About the technology

Insilico's technology is built around Insilico Cells™, which are genome-based mechanistic network models of common host organisms that are used to produce biologics. These models are refined and calibrated using real-life bioprocess measurements to become an individualized representation of the specific cells in silico. Based on simulations using such models, the behavior of cells in a bioprocess can be simulated and

Press Release



understood for an almost unlimited number of scenarios. Since those simulations can require significant computing power, Insilico uses supercomputing or cloud resources to complete them.

About Insilico

Insilico Biotechnology is a market-leading company providing predictive solutions for the Bioeconomy. An interdisciplinary team of experts offers mechanistic models, customized software, and a high performance computing platform for the simulation of living cells. For world-leading pharma and biotech companies Insilico's technology lowers time, risk and costs of development processes. Founded in 2001, Insilico is a privately held company based in Stuttgart.

Contact

Insilico Biotechnology AG
Dr. Daniel Horbelt | Business Development
T +49 711 460 594-14
F +49 711 460 594-10
daniel.horbelt@insilico-biotechnology.com